Changing demographics and immunity to vaccine preventable diseases in people with HIV in Ireland

• Published in: BMC infectious diseases Vol. 22; no. 1; pp. 1 - 582
• Main Authors: Kerr, C, Kelleher, M, Coughlan, S, Crowley, B, O'Reilly, E. J, Bergin, C
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 29.06.2022; BioMed Central; BMC
• Subjects: Age; Blood products; Chicken pox; Complications and side effects; Demographics; Demography; Encephalitis; Females; Fever; Food contamination & poisoning; Health risks; Hepatitis; Hepatitis A; Hepatitis B; HIV; HIV infection; Human immunodeficiency virus; Immunity; Immunization; Immunoglobulin G; Infections; Infectious diseases; Injection; Management; Measles; Morbidity; Mumps; Needlestick injuries; Outpatient care facilities; Patient outcomes; Public health; Risk; Risk factors; Risk groups; Rubella; Seroepidemiology; Serology; Statistics; Urban areas; Urban environments; Vaccination; Vaccines; Varicella; Varicella Zoster; Viral infections; Virus diseases; Viruses; Ireland; South America; Central America; Asia; Europe; Africa
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-022-07487-z

HIV infection is associated with an increased risk of morbidity and mortality from vaccine preventable infections. This research describes, in the context of changing patient demographics, the seroprevalence of vaccine preventable viral infections among attendees of the largest centre for HIV positive patients in Ireland. Baseline serum IgG results for measles, mumps, rubella, varicella zoster virus (VZV) & hepatitis A, as well as hepatitis B sAg, cAb and sAb results, were retrieved for 2534 clinic attendees attending in 2018. Results were available for between 990 and 2363 attendees (39-93%), depending on the test, and were compared with 2013 clinic data. There was a 35% increase in attendees in 2018 when compared to 2013. The largest increase was in attendees of South American origin. In 2018, males accounted for 73% of the entire cohort and the HIV acquisition risk for 48% of attendees was MSM. 47% of attendees were originally from Ireland. Among those tested, 33% were susceptible to at least one component of the MMR vaccine. 5% were VZV non-immune (significantly associated with younger age and the acquisition risk status of injection drug use). 21% were hepatitis A non-immune (significantly associated with younger age and being of European or South American origin). 32% were hepatitis B cAb seropositive (significantly associated with older age, injection drug use status and being originally from Africa). 3% demonstrated hepatitis B sAg positivity. 64% had hepatitis B sAb [greater than or equai to] 10mIU. In a cohort of attendees to an HIV clinic in a large urban setting, the susceptibility to several common vaccine preventable viral infections, in particular MMR and hepatitis A and B, was high. These results highlight the importance of proactive screening and immunisation to help protect this high risk patient group against vaccine preventable diseases.